دورية أكاديمية
Prognostic and predictive markers in liver limited stage IV colorectal cancer.
| العنوان: | Prognostic and predictive markers in liver limited stage IV colorectal cancer. |
|---|---|
| المؤلفون: | Rehman AH; Liverpool Hepatobiliary Unit, University Hospital Aintree NHS Foundation Trust, England, UK. Electronic address: ahrehman@doctors.org.uk., Jones RP; Liverpool Hepatobiliary Unit, University Hospital Aintree NHS Foundation Trust, England, UK., Poston G; Liverpool Hepatobiliary Unit, University Hospital Aintree NHS Foundation Trust, England, UK. |
| المصدر: | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2019 Dec; Vol. 45 (12), pp. 2251-2256. Date of Electronic Publication: 2019 Jun 27. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 8504356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2157 (Electronic) Linking ISSN: 07487983 NLM ISO Abbreviation: Eur J Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Original Publication: London ; New York : Academic Press, [1985- |
| مواضيع طبية MeSH: | Biomarkers, Tumor/*analysis , Colorectal Neoplasms/*pathology , Liver Neoplasms/*secondary , Liver Neoplasms/*surgery, Disease Progression ; Humans ; Neoplasm Staging ; Patient Selection ; Predictive Value of Tests ; Prognosis |
| مستخلص: | Colorectal cancer is the third most commonly diagnosed cancer among both men and women. Personalised treatment options remain complex, although there is broad agreement over which patients with colorectal liver metastases (CRLM) should and should not be offered resection. Decisions on an optimal management strategy involves careful assessment of both technical and oncological factors. In this review we aim to summarise current prognostic biomarkers for metastatic colorectal cancers, specifically patients considered for resection. A number of clinico-pathological factors have been identified as prognostically important with good internal validity, but limited external validity. Furthermore, these prognostic scoring systems do not take factor in modern chemotherapeutic agents and the disease modification these agents produce. Histopathological response to chemotherapy is of significant prognostic importance. Molecular markers can help predict the efficacy of a biological agent. An important prognostic factor of liver metastasis is the recognition that location of the primary colorectal cancer impacts on metastatic phenotype and represents difference in genotype, i.e. proximal tumours are more aggressive than distal tumours with an increased likelihood of disease progression. Several mutational molecular markers identified include microsatellite instability, BRAF, and KRAS/NRAS and combination mutations, which confer poorer outcomes. Accurate prognostication in patients with liver limited colorectal metastases remains crucial, as this allows tailoring treatment options to each disease and improving outcomes. Access to tissue before treatment remains a limitation although advances in ability to assess tumour biology by non-invasive methods are promising. (Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Biomarkers; Metastatic liver cancer; Microsatellite instability; Tumour biology |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20190708 Date Completed: 20200618 Latest Revision: 20200618 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.ejso.2019.06.038 |
| PMID: | 31279594 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1532-2157 |
|---|---|
| DOI: | 10.1016/j.ejso.2019.06.038 |